Adlai Nortye Biopharma Co., Ltd. announced that it had entered into a Global Licensing Agreement with Eisai Co.,Ltd. Under the terms of the Agreement, Adlai Nortye will have exclusive worldwide research, development, manufacture and commercialization rights to E7046, excluding Japan and part of Asia other than Mainland China.